Dr. Julie Lovshin is a Clinician Investigator and Assistant Professor of Medicine in the Division of Endocrinology and Metabolism, in the Temetry Department of Medicine at the University of Toronto. Clinically, Dr. Lovshin is a staff Endocrinologist at Sunnybrook Health Sciences Centre in Toronto, Ontario Canada, who specializes in diabetes clinical care.
Dr. Lovshin’s research training includes a PhD at the University of Toronto in the Institute of Medical Science, supervised by Dr. Daniel Drucker on incretin hormones, including GLP-1 and GLP-2. She completed her undergraduate Medical School training, Internal Medicine Residency and Post-Graduate Clinical Fellowship in Endocrinology and Metabolism at the University of Toronto. Dr. Lovshin then went on to pursue clinical research investigation as an Eliot Phillipson Scholar in the Temetry Department of Medicine at the University of Toronto in a Post-Doctoral Research Fellowship focused on investigating renal and hemodynamic functional pathways in Types 1 and 2 diabetes with Dr. David Cherney and Dr. Dan Drucker. During her fellowship, Dr. Lovshin also completed formal research methodology and epidemiology training at the Harvard School of Public Health, Boston, MA, USA.
Dr. Lovshin directs the Diabetes Complications Clinical Research Laboratory at Sunnybrook Health Sciences Research Centre, Toronto, Canada. Dr. Lovshin has authored more than 70 academic publications in the area of diabetes, and has served as invited speaker at numerous international conferences, given her expertise in both the science and clinical use of GLP-1 receptor agonists.
GLP-1 Medications Unpacked: The Science, the Hype and the Fit
Learning Objectives:
- Review and understand the science mechanisms rationale for the development of incretin-based therapies
- Discuss the clinical use of GLP-1R agonists in T2DM and Obesity, dubunking myths and media hype and focus on 15-years of clinical experience with the use of GLP-1RAs in Canada
- Discuss key clinical trials with GLP-1RAs in 2025, and discuss the future of GLP-1 based agents in development for T2DM/Obesity